Role of Risk Assessments in Viral Safety: An FDA Perspective

References

1. 1.↵
   ICH Q5A(R1): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origen. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva, Switzerland, 1999.
2. 2.↵
   ICH Q9: Quality Risk Management. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva, Switzerland, 2006.
3. 3.↵
   1. Garnick R.L.

   Experience with viral contamination in cell culture. Dev. Biol. Stand. 1996, 88, 49–56.

   OpenUrlPubMed
4. 4.↵
   1. Khan A.S.,
   2. Lubiniecki A.,
   3. King K.E.

   PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, Nov. 3–4, 2011, Rockville, MD. PDA J Pharm. Sci. Technol. 2012, 66(6), 502–11.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Rönninger S.,
   2. Holmes M.

   A risk-based approach to scheduling audits. PDA J. Pharm. Sci. Technol. 2009, 63(6), 575–588.

   OpenUrlAbstract/FREE Full Text